Although trans-rectal ultrasound (TRUS) is widely used for prostate imaging, there are drawbacks to this technique. Ultrasound imaging inherently produces speckle, which is the snowy pattern that results from random interference of echoes from tissue scatterers. This artifact reduces image contrast and hampers detection of lesions. Moreover, TRUS is not capable of distinguishing between soft and hard lesions. Tissue stiffness is known to be associated with pathology. Another shortcoming of conventional TRUS in prostate imaging is its limitations in imaging prostate brachytherapy seeds. This issue is important when permanent prostate brachytherapy is performed under TRUS guidance. Metallic brachytherapy seeds are often missed in an ultrasound image and consequently radiation dosage calculation cannot be done with confidence in the operative setting. We have developed a novel imaging modality, referred to as Vibro-acoustography, which incorporates many improvements over TRUS, i.e., it is noninvasive, speckle free, sensitive to tissue stiffness, and capable of imaging brachytherapy seeds at any orientation. Active extramural funded research programs to develop a superficial vibro-acoustic probe for general diagnostic imaging, and to investigate applications of vibro-acoustography in breast cancer have provided a strong impetus and background for the development of a trans-rectal vibro-acoustic (TRVA) probe. In this research, we plan to further develop and test this technique for prostate imaging applications. A prostate-specific TRVA probe will be designed and constructed in conjunction with the General Electric medical imaging group. The performance of TRVA for detecting prostate lesions in human subjects will be tested and compared to TRUS imaging. The ability of TRVA to guide minimally invasive prostate therapies and procedures including prostate brachytherapy and cyrotherapy will be evaluated and compared with the performance of ultrasound imaging. The potential for TRVA to map areas of the prostate which have experienced complete cryoablation following cryotherapy versus areas which may have been undertreated also exists. Such imaging capability has significant implications and translation potential towards providing a means of intraoperative quality assurance for this treatment modality. Successful completion of this project should provide a new class of imaging tools for prostate imaging and increase our abilities to detect and treat prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA091956-09
Application #
7919515
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
9
Fiscal Year
2009
Total Cost
$217,538
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Guerrico, Anatilde Gonzalez; Hillman, David; Karnes, Jeffery et al. (2017) Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. J Circ Biomark 6:1849454417720151
Hearn, Jason W D; AbuAli, Ghada; Reichard, Chad A et al. (2016) HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol 17:1435-1444
Spratt, Daniel E; Evans, Michael J; Davis, Brian J et al. (2015) Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res 75:4688-96
Lu, Ji; Lonergan, Peter E; Nacusi, Lucas P et al. (2015) The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol 193:690-8
Urban, Matthew W; Wang, Chenyi; Alizad, Azra et al. (2015) Complex background suppression for vibro-acoustography images. Ultrasonics 56:456-72
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Alshalalfa, Mohammed; Crisan, Anamaria; Vergara, Ismael A et al. (2015) Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int 116:556-67
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Ahmed, Kamran A; Davis, Brian J; Mynderse, Lance A et al. (2014) Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol 9:171
Wu, Qiang; Kohli, Manish; Bergen 3rd, H Robert et al. (2014) Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther 13:1067-77

Showing the most recent 10 out of 206 publications